Figure 1.
Figure 1. Design of JALSG CML207 phase 3 study. IM, imatinib.

Design of JALSG CML207 phase 3 study. IM, imatinib.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal